A retrospective case study of sunitinib treatment in three patients with Von Hippel-Lindau disease

References

• Gossage L, Eisen T: Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nature reviews Clinical oncology 2010, 7(5):277–288.
   PubMed Web of Science ®Google Scholar
• Shuin T, Yamasaki I, Tamura K, Okuda H, Furihata M, Ashida S: Von Hippel-Lindau disease: molecular pathological basis, clinical criteria, genetic testing, clinical features of tumors and treatment. Japanese journal of clinical oncology 2006, 36(6):337–343.
   PubMed Web of Science ®Google Scholar
• Gossage L, Eisen T, Maher ER: VHL, the story of a tumour suppressor gene. Nature reviews Cancer 2015, 15(1):55–64.
   PubMed Web of Science ®Google Scholar
• Faivre S, Demetri G, Sargent W, Raymond E: Molecular basis for sunitinib efficacy and future clinical development. Nature reviews Drug discovery 2007, 6(9):734–745.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. The New England journal of medicine 2007, 356(2):115–124.
   PubMed Web of Science ®Google Scholar
• Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A et al: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. The New England journal of medicine 2011, 364(6):501–513.
   PubMed Web of Science ®Google Scholar
• Kim HC, Lee JS, Kim SH, So HS, Woo CY, Lee JL: Sunitinib treatment for metastatic renal cell carcinoma in patients with von hippel-lindau disease. Cancer research and treatment : official journal of Korean Cancer Association 2013, 45(4):349–353.
   PubMedGoogle Scholar
• Jonasch E, McCutcheon IE, Waguespack SG, Wen S, Davis DW, Smith LA, Tannir NM, Gombos DS, Fuller GN, Matin SF: Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. Annals of oncology : official journal of the European Society for Medical Oncology 2011, 22(12):2661–2666.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, Bhalla IP, Small EJ, Weinberg V, Sein N, Simko J et al: von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. The Journal of urology 2008, 180(3):860–865; discussion 865–866.
   PubMed Web of Science ®Google Scholar
• Rini BI, Jaeger E, Weinberg V, Sein N, Chew K, Fong K, Simko J, Small EJ, Waldman FM: Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU international 2006, 98(4):756–762.
   PubMed Web of Science ®Google Scholar
• Oudard S, Elaidi R, Brizard M, Le Rest C, Caillet V, Deveaux S, Benoit G, Correas JM, Benoudiba F, David P et al: Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR group. Oncotarget 2016, 7(51):85306–85317.
   PubMedGoogle Scholar
• Roma A, Maruzzo M, Basso U, Brunello A, Zamarchi R, Bezzon E, Pomerri F, Zovato S, Opocher G, Zagonel V: First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: clinical outcome and patterns of radiological response. Familial cancer 2015, 14(2):309–316.
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhang J, Wang G, Xu J, Li Y, Guo Q, Zheng T, Zhang Y: Benefit of Sunitinib in the treatment of pulmonary primitive neuroectodermal tumors: a case report and literature review. Oncotarget 2016, 7(52):87543–87551.
   PubMedGoogle Scholar
• Jimenez C, Cabanillas ME, Santarpia L, Jonasch E, Kyle KL, Lano EA, Matin SF, Nunez RF, Perrier ND, Phan A et al: Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. The Journal of clinical endocrinology and metabolism 2009, 94(2):386–391.
   PubMed Web of Science ®Google Scholar
• Tsimafeyeu I: Sunitinib treatment of metastatic renal cell carcinoma in von Hippel-Lindau disease. Journal of cancer research and therapeutics 2015, 11(4):920–922.
   PubMed Web of Science ®Google Scholar
• Knickelbein JE, Jacobs-El N, Wong WT, Wiley HE, Cukras CA, Meyerle CB, Chew EY: Systemic Sunitinib Malate Treatment for Advanced Juxtapapillary Retinal Hemangioblastomas Associated with von Hippel-Lindau Disease. Ophthalmology retina 2017, 1(3):181–187.
   PubMedGoogle Scholar
• Ali T, Kandil D, Piperdi B: Long-term disease control with sunitinib in a patient with metastatic pancreatic neuroendocrine tumor (NET) associated with Von Hippel-Lindau syndrome (VHL). Pancreas 2012, 41(3):492–493.
   PubMed Web of Science ®Google Scholar
• Choi KH, Yu YD, Kang MH, Park DS: Sorafenib treatment for recurrent stage T1 bilateral renal cell carcinoma in patients with Von Hippel- Lindau disease: A case report and literature review. Canadian Urological Association journal = Journal de l'Association des urologues du Canada 2015, 9(9-10):E651–653.
   PubMed Web of Science ®Google Scholar
• Dahr SS, Cusick M, Rodriguez-Coleman H, Srivastava SK, Thompson DJ, Linehan WM, Ferris FL, 3rd, Chew EY: Intravitreal anti-vascular endothelial growth factor therapy with pegaptanib for advanced von Hippel-Lindau disease of the retina. Retina 2007, 27(2):150–158.
   PubMed Web of Science ®Google Scholar
• Wong WT, Liang KJ, Hammel K, Coleman HR, Chew EY: Intravitreal ranibizumab therapy for retinal capillary hemangioblastoma related to von Hippel-Lindau disease. Ophthalmology 2008, 115(11):1957–1964.
   PubMed Web of Science ®Google Scholar
• Metelo AM, Noonan H, Iliopoulos O: HIF2a inhibitors for the treatment of VHL disease. Oncotarget 2015, 6(27):23036–23037.
   PubMedGoogle Scholar